Inflammatory Bowel Diseases

Therapeutic drug monitoring

Drug

Infliximab

Inflammatory bowel disease

Tumor necrosis factor alpha

Disease

Psoriasis

Intensive care medicine

Adalimumab

Disease monitoring

Crohn's disease

Rheumatoid arthritis

Internal medicine

Biosimilar

Pharmacology

Immunology

Medicine

The Lancet. Gastroenterology & hepatology

Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory bowel disease (IBD). However, challenges remain and are hindering the widespread implementation of TDM in clinical practice. These barriers include identification of the optimal drug concentration to target, the lag time between sampling and results, and the proper interpretation of anti-drug antibody titres among different assays.

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives